IQVIA Holdings Inc. (0JDM.L)
USD 144.71
(-3.07%)
USD 144.71
(-3.07%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 5.23 Billion USD | -17.76% |
| 2022 | 5.02 Billion USD | 8.34% |
| 2021 | 4.64 Billion USD | 20.26% |
| 2020 | 3.85 Billion USD | 1.87% |
| 2019 | 3.78 Billion USD | 3.33% |
| 2018 | 3.66 Billion USD | 6.63% |
| 2017 | 3.43 Billion USD | 61.56% |
| 2016 | 2.12 Billion USD | 32.93% |
| 2015 | 1.6 Billion USD | 8.04% |
| 2014 | 1.48 Billion USD | 10.83% |
| 2013 | 1.33 Billion USD | 8.43% |
| 2012 | 1.23 Billion USD | 7.97% |
| 2011 | 1.14 Billion USD | 2.04% |
| 2010 | 1.11 Billion USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 1.37 Billion USD | 30.37% |
| 2024 Q1 | 1.03 Billion USD | -7.44% |
| 2024 Q2 | 1.05 Billion USD | 2.42% |
| 2023 Q4 | 1.11 Billion USD | -14.89% |
| 2023 Q3 | 1.31 Billion USD | 1.95% |
| 2023 Q1 | 1.25 Billion USD | -5.86% |
| 2023 Q2 | 1.28 Billion USD | 2.47% |
| 2023 FY | 4.13 Billion USD | -17.76% |
| 2022 Q3 | 1.24 Billion USD | 2.56% |
| 2022 Q1 | 1.24 Billion USD | -2.12% |
| 2022 Q4 | 1.33 Billion USD | 7.33% |
| 2022 Q2 | 1.21 Billion USD | -2.81% |
| 2022 FY | 5.02 Billion USD | 8.34% |
| 2021 Q1 | 1.11 Billion USD | -0.89% |
| 2021 Q2 | 1.11 Billion USD | -0.09% |
| 2021 Q3 | 1.13 Billion USD | 2.06% |
| 2021 FY | 4.64 Billion USD | 20.26% |
| 2021 Q4 | 1.27 Billion USD | 11.78% |
| 2020 Q1 | 930 Million USD | -6.44% |
| 2020 Q4 | 1.12 Billion USD | 14.2% |
| 2020 Q2 | 817 Million USD | -12.15% |
| 2020 Q3 | 986 Million USD | 20.69% |
| 2020 FY | 3.85 Billion USD | 1.87% |
| 2019 Q1 | 936 Million USD | -1.06% |
| 2019 FY | 3.78 Billion USD | 3.33% |
| 2019 Q2 | 941 Million USD | 0.53% |
| 2019 Q3 | 917 Million USD | -2.55% |
| 2019 Q4 | 994 Million USD | 8.4% |
| 2018 Q1 | 911 Million USD | -6.08% |
| 2018 FY | 3.66 Billion USD | 6.63% |
| 2018 Q4 | 946 Million USD | 3.28% |
| 2018 Q3 | 916 Million USD | 2.58% |
| 2018 Q2 | 893 Million USD | -1.98% |
| 2017 Q2 | 815 Million USD | 2.0% |
| 2017 Q1 | 799 Million USD | -5.11% |
| 2017 Q4 | 970 Million USD | 13.58% |
| 2017 Q3 | 854 Million USD | 4.79% |
| 2017 FY | 3.43 Billion USD | 61.56% |
| 2016 Q1 | 407.45 Million USD | -5.63% |
| 2016 Q3 | 432.63 Million USD | 1.46% |
| 2016 Q2 | 426.42 Million USD | 4.66% |
| 2016 FY | 2.12 Billion USD | 32.93% |
| 2016 Q4 | 842 Million USD | 94.62% |
| 2015 FY | 1.6 Billion USD | 8.04% |
| 2015 Q4 | 431.74 Million USD | 5.19% |
| 2015 Q3 | 410.42 Million USD | 5.1% |
| 2015 Q2 | 390.52 Million USD | 6.08% |
| 2015 Q1 | 368.14 Million USD | -5.42% |
| 2014 Q4 | 389.22 Million USD | 5.21% |
| 2014 Q3 | 369.96 Million USD | 2.49% |
| 2014 Q1 | 361.56 Million USD | -0.12% |
| 2014 FY | 1.48 Billion USD | 10.83% |
| 2014 Q2 | 360.96 Million USD | -0.17% |
| 2013 Q3 | 332.03 Million USD | 1.67% |
| 2013 Q4 | 361.98 Million USD | 9.02% |
| 2013 FY | 1.33 Billion USD | 8.43% |
| 2013 Q1 | 316.32 Million USD | -0.3% |
| 2013 Q2 | 326.57 Million USD | 3.24% |
| 2012 Q1 | 297.47 Million USD | 0.0% |
| 2012 Q3 | 301.48 Million USD | -4.8% |
| 2012 Q4 | 317.28 Million USD | 5.24% |
| 2012 FY | 1.23 Billion USD | 7.97% |
| 2012 Q2 | 316.69 Million USD | 6.46% |
| 2011 FY | 1.14 Billion USD | 2.04% |
| 2010 FY | 1.11 Billion USD | 0.0% |
| 2001 Q3 | 1.24 Billion USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | -236423.702% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -1734668.212% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 6247.906% |
| Agilent Technologies, Inc. | 3.46 Billion USD | -51.198% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -30150.014% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | -245.151% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -1347.118% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 1673901.917% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -2042.434% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | -175.104% |
| bluebird bio, Inc. | -4.03 Million USD | 130100.0% |
| Blueprint Medicines Corporation | 236.58 Million USD | -2114.435% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -35313.005% |
| Imunon, Inc. | -720 Thousand USD | 727733.836% |
| Adicet Bio, Inc. | -6.09 Million USD | 86013.414% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -1000.875% |
| Dynavax Technologies Corporation | 182.11 Million USD | -2776.722% |
| Editas Medicine, Inc. | -99.52 Million USD | 5363.845% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -1423.408% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -7070.132% |
| Exelixis, Inc. | 1.75 Billion USD | -198.067% |
| FibroGen, Inc. | 128.9 Million USD | -3964.265% |
| Geron Corporation | -123.5 Million USD | 4342.002% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -722.588% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -52070.882% |
| Illumina, Inc. | 2.74 Billion USD | -90.926% |
| Incyte Corporation | 3.44 Billion USD | -52.268% |
| Insmed Incorporated | 239.63 Million USD | -2086.242% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 1413.711% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -572.949% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 54866.883% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 1729142.904% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | -141.532% |
| Evolus, Inc. | 140.52 Million USD | -3628.136% |
| Myriad Genetics, Inc. | 476.4 Million USD | -999.706% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | -183.588% |
| OPKO Health, Inc. | 318.12 Million USD | -1546.827% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -379.326% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -900.302% |
| Verastem, Inc. | -62 Thousand USD | 8450100.0% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 80.248% |
| Waters Corporation | 1.76 Billion USD | -197.469% |
| Zoetis Inc. | 5.83 Billion USD | 10.199% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 39.131% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 65.587% |
| Biogen Inc. | 7.3 Billion USD | 28.254% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 11658.742% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 53.643% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 16909.09% |
| Homology Medicines, Inc. | -7.22 Million USD | 72571.988% |
| Nektar Therapeutics | 53.47 Million USD | -9696.552% |
| TG Therapeutics, Inc. | 219.1 Million USD | -2291.058% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 1794278.082% |
| Perrigo Company plc | 1.68 Billion USD | -211.771% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 26695.259% |